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Abstract The rapid and continuing progress in gene
discovery for complex diseases is fuelling interest in the
potential application of genetic risk models for clinical and
public health practice. The number of studies assessing the
predictive ability is steadily increasing, but they vary
widely in completeness of reporting and apparent quality.
Transparent reporting of the strengths and weaknesses of
these studies is important to facilitate the accumulation of
evidence on genetic risk prediction. A multidisciplinary
workshop sponsored by the Human Genome Epidemiology
Network developed a checklist of 25 items recommended
for strengthening the reporting of Genetic RIsk Prediction
Studies (GRIPS), building on the principles established by
prior reporting guidelines. These recommendations aim to
enhance the transparency, quality and completeness of
study reporting, and thereby to improve the synthesis and
application of information from multiple studies that might
differ in design, conduct or analysis.
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Introduction
The advent of genome-wide association studies has accel-
erated the discovery of novel genetic markers, in particular
single nucleotide polymorphisms (SNPs) that are associ-
ated with risk for common complex diseases.
Technological developments in large-scale genomic stud-
ies, such as whole genome sequencing, will facilitate the
discovery of novel of common SNPs, as well as of rare
variants, copy number variations, deletions/insertions,
structural variations (e.g., inversions), and epigenetic
effects that inﬂuence the regulation of gene expression.
These developments are fuelling interest in the translation
of this basic knowledge to health care practice. Knowledge
about genetic risk factors may be used to target diagnostic,
preventive and therapeutic interventions for complex dis-
orders based on a person’s genetic risk, or to complement
existing risk models based on classical non-genetic factors
such as the Framingham risk score for cardiovascular dis-
ease. Implementation of genetic risk prediction in health
care requires a series of studies that encompass all phases
of translational research [1, 2], starting with a compre-
hensive evaluation of genetic risk prediction.
Genetic risk prediction studies typically concern the
development and/or evaluation of models for the prediction
of a particular health outcome, but there is considerable
variation in their design, conduct and analysis. Genetic risk
models most frequently predict risk of disease, but they are
also being investigated for the prediction of prognostic
outcome, treatment response or treatment side effects. Risk
prediction models are used in research and clinical settings
to classify individuals into homogeneous groups e.g., for
randomization in clinical trials and for targeting preventive
or therapeutic interventions. The main study designs are
cohort, cross-sectional or case–control. The genetic risk
factors often are SNPs, but other variants such as
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123insertions/deletions, haplotypes and copy number varia-
tions can be included as well. The risk models are based
on genetic variants only, or include both genetic and non-
genetic risk factors. Risk prediction models are statistical
algorithms, which can be simple genetic risk scores (e.g.,
risk allele counts), or be based on regression analyses
(e.g., weighted risk scores or predicted risks) or on more
complex analytic approaches such as support vector
machine learning or classiﬁcation trees. Papers on genetic
risk prediction vary as to whether they present the
development of a risk model only, the validation of one
or more risk models only, or both development and val-
idation of a risk model [3]. Lastly, studies vary in the
measures used to assess model performance. So far,
assessments have nearly always included measures of
discrimination, but hardly any considered calibration [3].
Recent studies have additionally assessed measures of
reclassiﬁcation, despite debate on the appropriate use and
interpretation of these measures [4, 5].
So far most genetic prediction studies have shown that
the predictive performance of genetic risk models is poor,
with some exceptions such as those for age-related mac-
ular degeneration, hypertriglyceridemia and Crohn’s dis-
ease [6–8]. While the poor performance is most likely due
to the low number of variants that have been deﬁnitely
linked to a phenotype to date, many publications lack
sufﬁcient details to judge methodological or analytic
aspects. Information that is often missing includes details
in the description of how the study was designed and
conducted (e.g., how genetic variants were selected, how
risk models or genetic risk scores were constructed and
how risk categories were chosen), or how the results
should be interpreted. An appropriate assessment of the
study’s strengths and weaknesses is not possible without
this information. With increasing numbers of discovered
genetic markers that can be used in future genetic risk
prediction studies, it is crucial to enhance the quality of
the reporting of these studies, since valid interpretation
could be compromised by the lack of reporting of key
information. There is ample evidence that prediction
research often suffers from poor design and biases, and
these might have an impact also on the results of the
studies and on models of disease outcomes based on these
studies [9–11]. Although most prognostic studies pub-
lished to date claim signiﬁcant results [12, 13], very few
translate to clinically useful applications, in part because
study ﬁndings resulted from chance, methodological bia-
ses or the inclusion of risk factors that had not been
previously replicated. Just as for observational epidemi-
ological studies [14], poor reporting complicates the use
of the speciﬁc study for research, clinical, or public health
purposes and the deﬁciencies also hamper the synthesis of
evidence across studies.
Reporting guidelines have been published for various
research designs [15] and these contain many items that are
also relevant to genetic risk prediction studies. In particu-
lar, the guidelines for genetic association studies (STRE-
GA) have relevant items on the assessment of genetic
variants, and the guidelines for observational studies
(STROBE) have relevant items about the reporting of study
design. The guidelines for diagnostic studies (STARD) and
those for tumor marker prognostic studies (REMARK)
include relevant items about test evaluation, and the
REMARK guidelines include relevant items about risk
prediction [16–19]. However, none of these guidelines are
fully suited to genetic risk prediction studies, an emerging
ﬁeld of investigations with speciﬁc methodological issues
that need to be addressed, such as the handling of large
numbers of genetic variants (from 10 s to 10,000 s), which
come with greater challenges and ﬂexibility on how these
can be dealt with in the analyses.
The main goal of this paper is to propose and justify a
set of guiding principles for reporting results of Genetic
RIsk Prediction Studies (GRIPS). To minimize confusion
in the ﬁeld, these recommendations build on prior reporting
guidelines whenever possible. The intended audience for
the reporting guideline is broad and includes epidemiolo-
gists, geneticists, statisticians, clinician scientists and lab-
oratory-based investigators who undertake genetic risk
prediction studies, as well as journal editors and reviewers
who have to appraise the design, conduct and analysis of
such studies. In addition, it includes ‘users’ of such studies
who wish to understand the basic premise, design, and
limitations of genetic prediction studies in order to interpret
the results for their potential application in health care.
These guidelines are also intended to ensure that essential
data from genetic risk prediction studies are presented,
which will facilitate information synthesis as part of sys-
tematic reviews and meta-analyses.
Finally, it is important to emphasize that these recom-
mendations are guidelines only for how to report research;
the recommendations do not prescribe how to perform
genetic risk prediction studies. Nevertheless, we suggest
that increased transparency of reporting might have a
favorable effect on the quality of research, and thereby
improve the translation into practice, as has been the case
for the adoption of the CONSORT checklist in the
reporting of randomized controlled trials [20].
Development of the GRIPS Statement
The GRIPS Statement was developed by a multidisciplin-
ary panel of 25 risk prediction researchers, epidemiolo-
gists, geneticists, methodologists, statisticians and journal
editors, seven of whom were also part of the STREGA
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123initiative [17]. They attended a 2-day meeting in Atlanta,
GA, USA, in December 2009 sponsored by the Centers for
Disease Control and Prevention on behalf of the Human
Genome Epidemiology Network (HuGENet) [21]. Partici-
pants discussed a draft version of the checklist that was
prepared and distributed prior to the meeting. This draft
version was developed based on existing reporting guide-
lines, namely STREGA [17], REMARK [19], and STARD
[18]. These were selected from all available guidelines (see
www.equator-network.org) because of their focus on
observational study designs and genetic factors (STRE-
GA), prediction models (REMARK), and test evaluation
(REMARK and STARD). Methodological issues pertinent
to risk prediction studies were addressed in presentations
during the meeting. Workshop participants revised the
initial recommendations both during the meeting and in
extensive electronic correspondence after the meeting. To
harmonize our recommendations for genetic risk prediction
studies with previous guidelines, we chose the same
wording and explanations for the items wherever possible.
Finally, we tried to maintain consistency with previous
guidelines for the evaluation of risk prediction studies of
cardiovascular diseases and cancer [2, 22]. The ﬁnal ver-
sion of the checklist is presented in Table 1.
Scope of the GRIPS Statement
The GRIPS Statement is intended to maximize the trans-
parency, quality and completeness of reporting on research
methodology and ﬁndings in a particular study. Research-
ers can use the statement to inform their choice of study
design and analyses, but the guidelines do not support or
oppose the choice of any particular study design or method.
For example, the guidelines recommend that the study
population should be described, but do not specify which
population is preferred in a particular study.
Items presented in the checklist are relevant for a wide
array of observational risk prediction studies, because the
checklist focuses on the main aspects in the design and
analysis of risk prediction studies. GRIPS does not address
randomized trials that may be performed to test risk
models, nor does it speciﬁcally address decision analyses,
cost-effectiveness analyses, assessment of health care
needs or assessment of barriers to health care implemen-
tation [23]. Once the performance of a risk model has been
established, these next steps towards implementation
require further evaluation [24, 25]. For the reporting of
these studies, which go beyond the assessment of genetic
risk models as such, additional requirements apply. How-
ever, proper documentation of genetic predictive research
according to GRIPS might facilitate the translation of
research ﬁndings into clinical and public health practice.
How to use this paper
This paper illustrates and elaborates on the items of the
GRIPS Statement that are published in several journals. We
modeled this Explanation and Elaboration document along
the lines of those developed for other reporting guidelines
[26–29]. The GRIPS Statement consist of 25 items grouped
by article sections (title and abstract, introduction, meth-
ods, results and discussion). The discussion of each item in
this paper follows a standardized format. First, we illustrate
each item with one or more published examples of what we
consider to be transparent reporting, drawn from the
genetic risk prediction studies referenced in Table 2. Table
or ﬁgure numbers in the examples refer to the tables and
ﬁgures in the present manuscript, not the original article.
Second, for each item, we explain in detail the rationale for
its inclusion in the checklist. And third, we present details
about each item that need to be addressed to ensure
transparent reporting.
Frequently, papers about genetic risk prediction are
conducted using data from multiple populations. Many
studies have combined multiple datasets to develop the risk
model, for example by obtaining controls and cases from
different populations [7, 30–32], or have derived risk
models in multiple populations [33]. Studies may also use
one or more populations to validate the model in inde-
pendent samples. Readers need to be able to assess the
similarities and differences among these populations in
terms of the design of the study, selection of participants,
data collection and analyses. Differences in the study
designs and population characteristics that might impact
the validity and generalizability of the ﬁndings should be
reported. These may include ascertainment of participants,
distributions of age, sex and ethnicity as well as the
prevalence of risk factors, disease and co-morbidities [3].
Authors should describe any efforts made to harmonize the
assessment methods, if these were different. The essential
items that should be reported for each population are
marked in Table 1.
Finally, genetic risk models may also be applied to
predict other clinically relevant outcomes such as progno-
sis, treatment response and side effects of treatment. To
improve the readability of the paper, the paper focuses on
prediction of disease risk, but the items also apply to other
health outcomes as well.
The GRIPS Checklist
For each checklist item shown in Table 1, this section
provides examples of appropriate reporting from actual
scientiﬁc articles of genetic risk models for diseases and
health conditions, as well as an explanation of the
316 A. C. J. W. Janssens et al.
123Table 1 Reporting recommendations for evaluations of risk prediction models that include genetic variants
Title & Abstract
1 (a) Identify the article as a study of risk prediction using genetic factors.
(b) Use recommended keywords in the abstract: genetic or genomic, risk, prediction
Introduction
Background and rationale 2 Explain the scientiﬁc background and rationale for the prediction study
Objectives 3 Specify the study objectives and state the speciﬁc model(s) that is/are investigated.
State if the study concerns the development of the model(s), a validation effort, or both
Methods
Study design and setting 4
a Specify the key elements of the study design and describe the setting, locations and
relevant dates, including periods of recruitment, follow-up and data collection
Participants 5
a Describe eligibility criteria for participants, and sources and methods of selection of participants
Variables: deﬁnition 6
a Clearly deﬁne all participant characteristics, risk factors and outcomes. Clearly deﬁne genetic
variants using a widely-used nomenclature system
Variables: assessment 7
a (a) Describe sources of data and details of methods of assessment (measurement)
for each variable. (b) Give a detailed description of genotyping and other laboratory methods
Variables: coding 8 (a) Describe how genetic variants were handled in the analyses. (b) Explain how other
quantitative variables were handled in the analyses. If applicable, describe which groupings
were chosen, and why
Analysis: risk model construction 9 Specify the procedure and data used for the derivation of the risk model. Specify which
candidate variables were initially examined or considered for inclusion in models.
Include details of any variable selection procedures and other model-building issues.
Specify the horizon of risk prediction (e.g., 5-year risk)
Analysis: validation 10 Specify the procedure and data used for the validation of the risk model
Analysis: missing data 11 Specify how missing data were handled
Analysis: statistical methods 12 Specify all measures used for the evaluation of the risk model including, but not limited to,
measures of model ﬁt and predictive ability
Analysis: other 13 Describe all subgroups, interactions and exploratory analyses that were examined
Results
Participants 14
a Report the numbers of individuals at each stage of the study. Give reasons
for non-participation at each stage. Report the number of participants not genotyped,
and reasons why they were not genotyped
Descriptives: population 15
a Report demographic and clinical characteristics of the study population, including risk factors
used in the risk modeling
Descriptives: model estimates 16 Report unadjusted associations between the variables in the risk model(s) and the outcome.
Report adjusted estimates and their precision from the full risk model(s) for each variable
Risk distributions 17
a Report distributions of predicted risks and/or risk scores
Assessment 18 Report measures of model ﬁt and predictive ability, and any other performance measures,
if pertinent
Validation 19 Report any validation of the risk model(s)
Other analyses 20 Present results of any subgroup, interaction or exploratory analyses, whenever pertinent
Discussion
Limitations 21 Discuss limitations and assumptions of the study, particularly those concerning study design,
selection of participants, measurements and analyses, and discuss their impact
on the results of the study
Interpretation 22 Give an overall interpretation of results considering objectives, limitations, multiplicity
of analyses, results from similar studies, and other relevant evidence
Generalizability 23 Discuss the generalizability and, if pertinent, the health care relevance of the study results
Other
Supplementary information 24 State whether databases for the analyzed data, risk models and/or protocols are
or will become publicly available and if so, how they can be accessed
Funding 25 Give the source of funding and the role of the funders for the present study.
State whether there are any conﬂicts of interest
a Marked items should be reported for every population in the study
GRIPS Statement: explanation & elaboration 317
123importance and need for the item and helpful guidance
about details that constitute transparent reporting.
Title and Abstract
Item 1: (a) Identify the article as a study of risk prediction
using genetic factors. (b) Use recommended keywords
in the abstract: genetic or genomic, risk, prediction
Examples (Title) ‘‘Combining information from common
type 2 diabetes risk polymorphisms improves disease
prediction.’’ [34]
(Title) ‘‘Prediction model for prevalence and incidence
of advanced age-related macular degeneration based
on genetic, demographic, and environmental variables.’’
[6]
(Abstract) ‘‘Recent studies have evaluated whether
incorporating nontraditional risk factors improves coro-
nary heart disease (CHD) prediction models. This
1986–2001 US study aggregated the contribution of
multiple single nucleotide polymorphisms into a genetic
risk score (GRS) and assessed whether the GRS plus
traditional risk factors predict CHD better than traditional
risk factors alone.’’ [35]
(Abstract) ‘‘The degree to which currently known
genetic variants can improve the prediction of CHD risk
beyond conventional risk factors in this disorder was
investigated.’’ [36]
Explanation Public bibliographic databases have
become an essential tool in knowledge synthesis and dis-
semination and a key source for identifying studies. To
date, there is no single strategy that retrieves all or most
papers on genetic risk prediction in these databases.
Table 2 shows that the 24 studies of genetic risk prediction
cited in this paper have used 17 different terms in their
titles and one study made no reference to genetic factors at
all [37]. PubMed Clinical Queries has implemented stan-
dardized search strategies for retrieving clinical prediction
guides [38] and prognosis studies in general [39], but these
are inefﬁcient strategies to retrieve genetic risk prediction
studies. The broad versions of both types of PubMed
Clinical Queries were able to ascertain most of the listed
papers, but at the same time many other studies not related
to this topic (Table 2). To facilitate identiﬁcation and
indexing, authors are encouraged to exploit all three
opportunities, namely title, abstract and Medical Subject
Headings (MeSH terms), to help ensure the capture of the
article in the clinical queries and routine PubMed searches.
In the abstract, authors should explicitly describe their
work as a study of genetic risk prediction by using the
three keywords: ‘‘genetic’’ (or ‘‘genomic’’), ‘‘risk’’, and
‘‘prediction’’. These words do not need to be mentioned
in a speciﬁc combination or order. If the report focuses on
genetic risk prediction as a main objective, authors are
advised to mention the keywords in the title. The use of
the keyword ‘‘genetic’’ or ‘‘genomic’’ is particularly
important because a variety of genetic variants exists,
such as chromosomes, SNPs, haplotypes or copy number
variations. It will be difﬁcult to retrieve all relevant
studies if authors only use the speciﬁc terminology and
not a broad descriptor like ‘‘genetic variant’’. Table 2
shows that the combination of the keywords was by far
more speciﬁc in identifying the prediction studies that are
cited in this paper as compared with the PubMed Clinical
Queries. The use of these keywords is also essential when
risk prediction is not the main objective of a study, for
example when prediction analysis is part of genome-wide
association studies [40]. To ensure that these articles are
identiﬁable, authors should mention the prediction anal-
ysis in the abstract as well.
MeSH terms are another opportunity to identify an
article as a study of genetic risk prediction, but this is
often not under control of the author. The articles listed in
Table 2 have been given a variety of MeSH terms and no
single term or combination of terms would have retrieved
all papers. To facilitate future synthesis of studies, we
recommend that studies on this topic at least use the
MeSH terms ‘‘genetic predisposition to disease’’, ‘‘risk
assessment’’ and ‘‘predictive value of tests’’. These three
terms are analogous to the keywords ‘‘genetic’’, ‘‘risk’’
and ‘‘prediction’’. Each MeSH term alone retrieved 18 of
the articles listed in Table 2, and over 50,000 other arti-
cles (results not shown). The exact combination of the
three MeSH terms did not retrieve any of these studies,
but also only a little over 100 other papers in total.
Consequently, assigning the three MeSH terms to genetic
risk prediction studies potentially allows for a very spe-
ciﬁc search strategy to retrieve future articles.
Introduction
Item 2: Explain the scientiﬁc background and rationale
for the prediction study
Example ‘‘Knowledge about genetic and epidemiologic
associations with the leading cause of blindness among the
elderly, age-related macular degeneration, has grown
exponentially in recent years. Several genetic variants with
strong and consistent associations with AMD have recently
been identiﬁed. We also know that in addition to age,
ethnicity, and family history, there are modiﬁable factors:
smoking, nutritional antioxidants and omega-3 fatty acid
intake, and overall and abdominal adiposity. However, it
remains unknown whether all these genetic and environ-
mental factors act independently or jointly and to what
extent they as a group can predict the occurrence of age-
318 A. C. J. W. Janssens et al.
123related macular degeneration (AMD) or progression to
advanced AMD from early and intermediate stages. Such
information might be useful for screening those at high risk
due to a positive family history or having signs of early or
intermediate disease, among whom some progress to
advanced stages of AMD with visual loss. Early detection
could reduce the growing societal burden due to AMD by
targeting and emphasizing modiﬁable habits earlier in life
and recommending more frequent surveillance for those
highly susceptible to the disease.’’ [6]
Explanation The background should inform the reader
what is already known on the topic, and what gaps in
knowledge justify conducting the present study. Relevant
background information should include, but is not limited
to, the following two topics:
First, what is known about the role of genetic factors in
the outcome of interest, and in particular about the genetic
variants that are being considered for inclusion in the
prediction model? Such information could include a sum-
mary of how many genetic variants have been discovered
and possibly what is the range of their observed effect
sizes.
Second, the introduction should inform what alternative
models for risk prediction are available or have been
Table 2 Genetic terminology used in titles of genetic risk prediction studies and retrieval of the studies in PubMed
Terminology Reference PubMed clinical query Genetic risk
prediction
b
Clinical prediction guides Prognosis
Narrow Broad Narrow Broad
Candidate gene genotypes [55] No Yes No Yes No
DNA variants [33] No Yes No Yes Yes
Gene polymorphisms [54] No Yes Yes Yes Yes
Gene variants [32] No No Yes Yes No
Genetic approaches [92] No Yes No Yes Yes
Genetic prediction [93] No Yes No Yes Yes
Genetic risk factors [52] No Yes Yes Yes Yes
Genetic risk score [35] No Yes Yes Yes Yes
Genetic variables [6] No Yes No Yes Yes
Genetic variants [67]N o N o N o N o N o
[31] No Yes Yes Yes Yes
Genetic variation [56] No Yes Yes Yes Yes
Genotype score [48] No Yes No Yes Yes
Molecular prediction [7] No Yes Yes Yes Yes
Polygenic determinants [8]N o N o N o N o N o
Polymorphisms [51] No Yes No Yes Yes
[42] No Yes No Yes Yes
[47] No Yes Yes Yes No
[34] No Yes No Yes Yes
[43] No Yes Yes Yes Yes
[36] No Yes No Yes Yes
Susceptibility gene variants [30]N o N o N o N o N o
Weighted genetic score [57] No No No Yes Yes
No mention of genetics in title [37] Yes Yes No Yes Yes
Retrieved (out of 24) 1 19 9 21 18
(genetic[ti] or gene[ti] or DNA[ti]
or polymorphism*[ti] or molecular[ti]
or polygenic[ti]) AND\query[
a
4,772 156,641 18,090 67,931
(Genetic or genomic) risk prediction
b 1,597
Retrieval data were obtained from PubMed queries conducted in February 2010
a The ﬁrst part of this strategy captures the genetic descriptions from the titles of all papers listed in the table, except the one that had no mention
of genetics in the title. The second part refers to the query listed in the column heading
b The search strategy used in the last column is described in the last row
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123investigated for the outcome of interest, including models
that are based on fewer genetic variants, the same variants,
non-genetic risk factors or a combination of genetic and
non-genetic factors. The assessment of the performance of
these risk models can provide a reference value for the
evaluation of the risk model under study [13, 41]. A
comparison with earlier studies is most informative when
essential information about the comparability of the studies
is provided. Such information may include details about the
setting (see below) and the age, sex and ethnicity of the
population investigated.
For some topics, summarizing this information system-
atically would require formal systematic reviews of
extensive bodies of literature and hundreds of pages, far
beyond the typical short introduction of most research
papers. Therefore, we recommend that the authors should
be concise in reviewing the status of current risk research
on the topic of interest and how the current study proposes
to build on this existing evidence.
Item 3: Specify the study objectives and state the speciﬁc
model(s) that is/are investigated. State if the study concerns
the development of the model(s), the validation effort
of the model(s), or both
Examples ‘‘We examined subjects in two large Scandina-
vian prospective studies with a median follow-up period of
23.5 years to determine whether these genetic variants
alone or in combination with clinical risk factors might
predict the future development of type 2 diabetes and
whether these variants were associated with changes in
insulin secretion or action over time.’’ [33]
‘‘The present study was designed to evaluate whether
the ﬁndings of Zheng et al. could be replicated in a
population-based sample of American Caucasian men and
to evaluate how the combination of SNP genotypes and
family history function in prediction models for prostate
cancer risk and for prostate cancer-speciﬁc mortality.’’
[31]
Explanation Objectives refer to the speciﬁc research
questions that are investigated in the study. For genetic risk
prediction studies, the objectives should specify which
models are investigated for the prediction of which out-
come in which population and setting. Furthermore,
authors should state whether the report concerns the
development of a novel risk model (and if so, whether
some sort of internal or external validation is performed) or
about a replication or validation of an earlier model.
Finally, any planned subgroup and interaction analyses
should be speciﬁed, including a priori hypotheses or a
statement that subgroup and interaction effects were
explored without any hypothesis.
Methods
Item 4: Specify the key elements of the study design
and describe the setting, locations and relevant dates,
including periods of recruitment, follow-up and data
collection
Examples ‘‘The Rotterdam Study is a prospective, popu-
lation-based, cohort study among 7,983 inhabitants of a
Rotterdam suburb, designed to investigate determinants of
chronic diseases. Participants were aged 55 years and
older. Baseline examinations took place from 1990 until
1993. Follow-up examinations were performed in
1993–1994, 1997–1999, and 2002–2004. Between these
exams, continuous surveillance on major disease outcomes
was conducted. Information on vital status was obtained
from municipal health authorities.’’ [42].
‘‘A cohort of 2,576 men and 2,636 women from a
general population (aged 30–65 years at inclusion) partic-
ipated in the DESIR longitudinal study and were clinically
and biologically evaluated at inclusion, at 3-, 6-, and 9-year
visits.’’ [43]
Explanation Key elements about the study design
include whether the analyses were performed in: a cohort
study, which follows a group of individuals over time to
identify incident cases of disease; a cross sectional study,
which examines prevalent disease in a deﬁned population;
or a case–control study, which compares individuals with
the trait of interest to those without [17, 29, 44]. Setting
refers to how participants were recruited, for example
through hospitals, outpatient clinics, screening centers or
registries, and location refers to the country, region and
cities, if relevant. Stating the dates of data-collection rather
than the duration of the follow-up helps to place the study
in historical context and is particularly important in the
context of changes in diagnostic methods (e.g., imaging
and use of biomarkers), and changes in the assessment of
genotype and other risk factors.
Researchers should also state whether the data were de
novo collected speciﬁcally for the purpose stated in the
introduction, or whether the analyses were conducted using
previously collected data [29]. The secondary use of
existing data is not necessarily less credible, but a state-
ment might help to explain limitations in the study,
including, but not limited to, relevant data not being
assessed or the presence of peculiar population
characteristics.
Item 5: Describe eligibility criteria for participants,
and sources and methods of selection of participants
Examples (Eligibility criteria) ‘‘The diagnosis of diabetes
in case subjects was based on either current treatment with
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hyperglycemia if treated with diet alone. Patients with
conﬁrmed diagnosis of monogenic diabetes and those
treated with regular insulin therapy within 1 year of diag-
nosis were excluded. Case subjects in this study had an age
at diagnosis between 35 and 70 years, inclusive. Control
subjects had not been diagnosed with diabetes at the time
of recruitment or subsequently and were excluded if there
was evidence of hyperglycemia during recruitment (fasting
glucose[7.0 mmol/l, A1C[6.4%) or if they were
[80 years old.’’ [45]
(Sources and methods of selection) ‘‘The study popu-
lation consisted of 283 women with previous gestational
diabetes mellitus who were admitted to the Department of
Obstetrics, Copenhagen University Hospital, Rigshospita-
let, Denmark, during 1978–1996 and who had participated
in a follow-up study during 2000–2002.’’ [32]
Explanation The predictive performance of a risk model
might vary with the population in which the test is applied,
and is preferably assessed by testing a random sample of
individuals from the population at risk of the disease or
outcome. The eligibility criteria, source and methods of
selection of the study participants thus inform readers
about the assumed target population for testing as well as
about the representativeness of the study population.
Knowledge of the selection criteria is essential in
appraising the validity and generalizability of the study
results. Eligibility criteria may be presented as inclusion
and exclusion criteria, specifying characteristics such as
age, sex, ancestry, ethnicity and/or geographical region,
and, for case–control studies, diagnosis and comorbidity.
The source refers to the populations from which the par-
ticipants were selected and to the methods of selection—
whether participants were, for example, randomly invited,
referred or self-selected. The diagnostic criteria should be
clearly described, including references to standards, if
applicable.
For cohort and cross-sectional studies, the population
base from which participants were invited (e.g., from a
general population, speciﬁc region or hospital) should be
speciﬁed. Depending on the aim of the cohort, typical
eligibility criteria may include age, sex, ethnicity, speciﬁc
risk factors, and for cohorts of patients, diagnosis, disease
duration or stage, and comorbidity [29].
For case–control studies, one should specify the (diag-
nostic) criteria that were used to select cases, and the cri-
teria for selecting the controls. The extent to which controls
were screened for absence of symptoms related to the
disease or outcome under study should be described.
Description of the criteria should enable understanding of
the spectrum of disease involved. Case–control studies
sometimes compare very severe cases with very healthy
controls, particularly if the data were previously collected
primarily for gene discovery [8, 46]. Such stringent
selection of participants is an effective strategy for gene
discovery, but predictive performance might be overesti-
mated compared with assessment in unselected populations
where controls might have early symptoms or risk factors
of disease. Furthermore, for case–control studies, it is
important to specify whether cases and controls were
matched and how, as overmatching might affect the pre-
dictive power of that factor in the sample relative to its
predictive power in an unmatched population.
Item 6: Clearly deﬁne all participant characteristics, risk
factors and outcomes. Clearly deﬁne genetic variants using
a widely-used nomenclature system
Examples (Predictors) ‘‘We selected six SNPs from six loci
on the basis of their association with levels of LDL or HDL
cholesterol in at least one previous study. These six SNPs
were, for association with LDL cholesterol, APOB (apoli-
poprotein B, rs693), PCSK9 (proprotein convertase sub-
tilisin/kexin type 9, rs11591147), and LDLR (low-density
lipoprotein receptor, rs688); and for association with HDL
cholesterol, CETP (cholesteryl ester transfer protein,
rs1800775), LIPC (hepatic lipase, rs1800588), and LPL
(lipoprotein lipase, rs328).’’ [47]
(Predictors) Another example is provision of the infor-
mation in tabular form (See Table 3)[ 48].
(Predictors) ‘‘We deﬁned a positive self reported family
history of diabetes as a report that one or both parents had
diabetes; this deﬁnition is more than 56% sensitive and
97% speciﬁc for conﬁrmed parental diabetes. […]W e
considered diabetes to be present in a parent when medi-
cation was prescribed to control the diabetes or when the
casual plasma glucose level was 11.1 mmol per liter or
higher or 200.0 mg per deciliter or higher at any exami-
nation.’’ [48]
(Outcomes) ‘‘The prespeciﬁed composite end point of
cardiovascular events was deﬁned as myocardial infarction,
ischemic stroke, and death from coronary heart disease.
Myocardial infarction was deﬁned on the basis of codes
410 and I21 in the International Classiﬁcation of Diseases,
9th Revision and 10th Revision (ICD-9 and ICD-10),
respectively. Ischemic stroke was deﬁned on the basis of
codes 434 or 436 (ICD-9) and I63 or I64 (ICD-10).’’ [47]
Explanation All participant characteristics, genetic and
non-genetic risk factors, and outcomes that are considered
and used in the analyses, should be deﬁned and described
unambiguously. Disease outcomes should be deﬁned by
reference to established diagnostic criteria or justiﬁcation
of study-speciﬁc criteria, if such are employed. Both the
selection of genetic and non-genetic risk factors should be
clariﬁed. Authors should specify whether all known risk
factors are included, and, if not, why some are excluded.
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nomenclature [49]. For example, SNPs could be presented
with rs numbers with allusion to the pertinent reference
database and build (e.g., HapMap release 27) [50]. When
proxies (surrogate markers) are considered, the correlation
with the intended variant should be quantiﬁed, for example
in terms of R
2 along with the population used to derive the
correlation. When variants are obtained by imputation, the
imputation method and reference database should be
described along with an estimate of the quality of the
imputation.
Item 7: (a) Describe sources of data and details of methods
of assessment (measurement) for each variable. (b) Give
a detailed description of genotyping and other laboratory
methods
Examples (Sources of data) ‘‘Phenotyping was performed
by the participating gastroenterologist from each university
medical center by reviewing a patient’s chart retrospec-
tively.’’ [7]
(Sources of data) ‘‘All clinical measurements were
performed in practice by [the ﬁrst author] (ﬁrst measure-
ment) and a nurse practitioner (second, third and fourth
measurements with in-between periods of 3 months).’’ [51]
(Methods of assessment) ‘‘Weight was measured in
underwear to the nearest 0.1 kg on Soehnle electronic
scales. We measured height in bare feet to the nearest
1 mm by using a stadiometer with the participant standing
erect with head in the Frankfort plane. We calculated body
mass index as weight (kilograms)/height (metres) squared.
We measured waist circumference, taken as the smallest
circumference at or below the costal margin, with partici-
pants unclothed in the standing position by using a ﬁbre-
glass tape measure at 600 g tension. We measured systolic
blood pressure and diastolic blood pressure twice in the
sitting position after 5 min rest with the Hawksley random
zero sphygmomanometer. We took the average of the two
readings to be the measured blood pressure. We took
venous blood in the fasting state or at least 5 h after a light,
fat free breakfast, before a 2 h 75 g oral glucose tolerance
test was done. Serum for lipid analyses was refrigerated at
-4 C and assayed within 72 h. We used a Cobas Fara
centrifugal analyzer (Roche Diagnostics System, Nutley,
NJ) to measure cholesterol and triglyceride concentrations.
We measured high density lipoprotein cholesterol by pre-
cipitating non-high density lipoprotein cholesterol with
dextran sulfate-magnesium chloride with the use of a
centrifuge and measuring cholesterol in the supernatant
ﬂuid. We used the Friedewald formula to calculate low
density lipoprotein cholesterol concentration.’’ [52]
(Outcomes) ‘‘Women with gestational diabetes mellitus
in the years 1978–1985 were diagnosed by a 3 h, 50 g oral
glucose tolerance test (OGTT), whereas women with ges-
tational diabetes mellitus in 1987–1996 were diagnosed by
a 3 h, 75 g OGTT.’’ [32]
Table 3 Example Table: Description of genetic variants used in the analyses
SNP Locus Chromosome Locus relative to gene Risk allele Source
rs10923931 NOTCH2 1 Intron 5 T Zeggini et al.
rs10490072 BCL11A 2 3’ of gene T Zeggini et al.
rs7578597 THADA 2 Missense, exon 24 T Zeggini et al.
rs1470579 IGF2BP2 3 Intron 2 C Saxena et al.
rs1801282 PPARg 3 Intron 1 C Saxena et al.
rs4607103 ADAMTS9 3 Intron 2 C Zeggini et al.
rs7754840 CDKAL1 6 Intron 5 C Saxena et al.
rs9472138 VEGFA 6 3’ of gene T Zeggini et al.
rs864745 JAZF1 7 Intron 1 T Zeggini et al.
rs13266634 SLC30A8 8 Missense, exon 8 C Saxena et al.
rs10811661 CDKNA/2B 9 5’ of gene T Saxena et al.
rs1111875 HHEX 10 3’ of gene C Saxena et al.
rs12779790 CDC123,CAMK1D 10 3’ of gene G Zeggini et al.
rs7903146 TCF7L2 10 Intron 6 T Saxena et al.
rs5219 KCNJ11 11 Missense, exon 1 T Saxena et al.
rs689 INS 11 Intron 1 T Meigs et al.
rs1153188 DCD 12 5’ of gene A Zeggini et al.
rs7961581 TSPAN8, LGR5 12 5’ of gene C Zeggini et al.
Adapted from [48]
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of matrix-assisted laser desorption–ionization time of-ﬂight
mass spectrometry on a MassARRAY platform (Seque-
nom), as described previously. All SNPs were in Hardy–
Weinberg equilibrium (P[0.001). The genotyping suc-
cess rate was 96%. Using 15 samples analyzed in qua-
druplicate, we found the genotyping error rate to be
\0.7%.’’ [47]
Explanation Apart from the selection and deﬁnitions of
the variables, the sources and methods used for the
assessment can impact the quality of the study. Important
quality concerns are the potential for misclassiﬁcation of
risk factors and outcomes, as well as the accuracy of
genotyping [29]. Sources of data basically refer to who did
the data collection and how. Were the data collected by
research physicians or trained students? Were question-
naires completed in an interview or based on self-report,
and was the genotyping performed in house or by a spe-
cialized laboratory? Methods of assessment refer to the
speciﬁc techniques or questionnaires that were used. If
methods have been published previously, provide a refer-
ence. The laboratory procedures used to measure bio-
markers should be described in sufﬁcient detail for others
to be able to perform them and evaluate the generalizability
of prediction models that include them. For less widely-
used assessments, such as questionnaires and procedures
that are developed by the researchers themselves, authors
should report validity and reliability information about the
quality of the assessment [53]. When different assessments
are used at baseline and follow-up (e.g., baseline assess-
ments done by research physicians and follow-up assess-
ments obtained from medical records of the general
practitioner) these should be explained. When there is an
arbitration process for outcomes (e.g., centralized team
arbitrating on outcomes based on information contributed
by local investigators in peripheral centers), this process
should be speciﬁed.
Item 8: (a) Describe how genetic variants were handled
in the analyses. (b) Explain how other quantitative
variables were handled in the analyses. If applicable,
describe which groupings were chosen, and why
Examples (Genetic variants) ‘‘Using these 18 SNPs, we
constructed a genotype score ranging from 0 to 36 on the
basis of the number of risk alleles [see Table 3 for coding
of the risk alleles].’’ [48]
(Genetic variants) ‘‘For the ﬁrst analysis of the effects of
the polymorphic DNA variants, we used additive genetic
models. In addition, we tested dominant and recessive
alternative models for the best ﬁt […]. Multivariate linear
regression analyses were used to test correlations between
genotype and phenotype. Non-normally distributed vari-
ables were log transformed before analysis. The effect size
of a genetic or clinical risk factor on the risk of type 2
diabetes was calculated from multivariate regression
analysis, with adjustment for age and sex, with the use of
Nagelkerke R square. We estimated the predictive value of
a combination of risk alleles (each person could have 0, 1,
or 2 of them, for a total of 22) in 11 genes, which signif-
icantly predicted the risk of diabetes by deﬁning subjects
with more than 12 risk alleles (about 20%) as being at high
risk and those with fewer than 8 risk alleles (about 20%) as
being at low risk.’’ [33]
(Other variables) ‘‘Multivariate unconditional logistic
regression analysis was performed to evaluate the rela-
tionships between prevalence or progression of AMD and
all the genotypes plus various risk factors, controlling for
age (70 years or older versus younger than 70), sex, and
education (high school or less versus more than high
school), cigarette smoking (never, past, or current), and
body mass index (BMI), which was calculated as the
weight in kilograms divided by the square of the height in
meters (\25, 25–29.9, and 30?).’’ [6]
Explanation There are many approaches to data anal-
ysis of genetic variants; thus, speciﬁcation and clariﬁca-
tion of this handling is particularly relevant. Genetic
variants may be entered in regression analysis separately
as dominant or recessive effects e.g., [54, 55], per allele
(additive or log-additive) effects [32], or genotype cate-
gories [42, 56]. Any of these three approaches can be
followed depending on what was the best ﬁtting genetic
model for each variant [6–8]. Alternatively, genetic
variants may be entered combined as risk scores [33, 47,
52]. Risk scores often simply sum the number of risk
alleles or genotypes (unweighted), or sum their beta-
coefﬁcients from regression analyses (weighted). When
using risk scores, authors should explain which of the
alleles or genotypes is considered as the risk variant, as
this is not necessarily the less common (minor) variant
(see Table 3). The description of the coding of the
genetic variants should enable other researchers to repli-
cate the analyses for validation or updating of the risk
model.
Quantitative variables can be handled as continuous or
be categorized. Transformations may be required when the
relationships between the variables and the outcome are not
linear, and these should be speciﬁed. Frequently, quanti-
tative variables are categorized before inclusion in the
analyses. A well-known example is body mass index,
which is categorized as underweight, normal weight,
overweight and obese. The rationale and thresholds used
for categorization should be explained, particularly when
they deviate from commonly used cut-offs based on clin-
ical or epidemiological studies.
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for the derivation of the risk model. Specify which
candidate variables were initially examined or considered
for inclusion in models. Include details of any variable
selection procedures and other model-building issues.
Specify the horizon of risk prediction (e.g., 5-year risk)
Examples (Model derivation) ‘‘We constructed multivari-
able proportional-hazards models to examine the associa-
tion between the genotype score and the time to the ﬁrst
cardiovascular event, excluding subjects who had had a
previous myocardial infarction or ischemic stroke. We ﬁrst
conﬁrmed that the proportional-hazards assumption was
met. The hazard ratio for the genotype score as a contin-
uous measure was estimated in a model adjusting for all 14
available baseline covariates. Cumulative incidence curves
were constructed according to the genotype score with the
use of Cox regression analysis.’’ [47]
(Variable selection) ‘‘Twenty-three candidate genes
involved in the pathogenesis of inﬂammation and myo-
cardial ischemia–reperfusion injury were selected a priori
based on previous transcription proﬁling in humans and
animal models, pathway analysis, a review of linkage and
association studies reported in the literature, and expert
opinion. Forty-eight SNPs were subsequently selected in
these process-speciﬁc candidate genes, based on literature
review, genomic context, and predictive analyses with an
emphasis on functionally important variants.’’ [54]
(Model building issues) ‘‘Both univariate and multivar-
iate odds ratios (ORs) were calculated with a binary-
logistic regression model … to evaluate the relationship
between polymorphisms and prevalent CVD. For that
purpose, dummy variables were created using the homo-
zygous wild-type genotype as reference category. Age and
gender, both demographic variables, were incorporated in
both the univariate as well as in the multivariate linear
regression analyses … Adjustment for potential con-
founders was performed by incorporating smoking, alco-
hol, diabetes mellitus, waist circumference, serum
creatinine, mean systolic and diastolic blood pressure,
microalbuminuria and dyslipidaemia into these models. To
avoid collinearity, waist circumference was used instead of
waist-to-hip ratio or body mass index and condensed
measures such as diabetes and dyslipidaemia were used, as
deﬁned earlier.’’ [51]
Explanation Because of the potential for ﬂexibility in
the derivation of the risk model, authors need to clarify
why and how they constructed the model as they did and
which data they used. This clariﬁcation includes a speci-
ﬁcation of the variables, deﬁned in item 6, that were ini-
tially considered and which procedures were followed for a
ﬁnal selection (e.g., backward deletion or forward inclu-
sion, and the criteria for deletion and inclusion), if
applicable. Clariﬁcation also includes a speciﬁcation of the
study participants included in the analysis, if different from
the total study population, transformations of the variables,
the choice of statistical model (e.g., logistic or Cox pro-
portional hazards models), and the handling of interaction
effects between predictors in the model (see also item 13).
The speciﬁcation also concerns the rationale for con-
structing separate models for subgroups, e.g., for different
ethnic groups, or including the stratiﬁcation variable as a
variable or interaction effect in a model for the total
population.
Authors should also specify and explain the horizon of
the risk prediction, when appropriate (e.g., in cohort stud-
ies, whether the model predicts, for instance, 5-year or
lifetime risk). When more complicated risk prediction
models are developed using statistical learning methods
such as regularized regression or support vector machines,
these should be explained and speciﬁed in sufﬁcient detail
that others can implement these models in other data sets.
For some more complex ‘‘black box’’ models (such as
random forests) this may require making a software
implementation of the ﬁnal model available. The descrip-
tion of the data used should include whether a selection of
the population was used for the derivation of the model,
how this subpopulation was selected, and how censored
data were handled in cohort studies.
Some studies aim only to validate and further apply an
already existing model. In this case, it should simply be
stated that a previous model was used with appropriate
reference to the previous study or studies that developed
the model along with a succinct description of its features.
Item 10: Specify the procedure and data used
for the validation of the risk model
Example ‘‘The internal validity of the prediction models
was assessed using bootstrapping techniques. A total of
100 random bootstrap samples were drawn with replace-
ment from the [total] group of 1,337 patients. The dis-
criminative accuracy of the 100 prediction models as ﬁt on
these bootstrap samples was determined for each bootstrap
sample and for the original group (n = 1,337). This com-
parison gives an impression of how ‘‘overoptimistic’’ the
model is, i.e., how much the performance of the model
would deteriorate when applied to a new group of similar
patients.’’ [36]
‘‘Evaluation of model predictive performance using the
same dataset used for ﬁtting the model usually leads to a
biased assessment. To obtain an unbiased assessment of
discriminatory power of the multivariate regression mod-
els, a tenfold cross-validation was used in the ROC analysis
and in the IDI analysis. Tenfold crossvalidation randomly
divides the data into ten (roughly) equal subsets and
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remaining subset as validation until each of the ten subsets
has been used exactly once as validation data.’’ [57]
Explanation Assessment of the risk model in the same
population as that from which the model was derived
generally leads to more positive conclusions than when the
evaluation is conducted in an independent population [58].
Therefore, validation of the risk model, reassessing the
performance of the model in another dataset, is an essential
part of model evaluation [59], especially when models are
developed with the speciﬁc intention to apply them in
health care. There are two main types of validation:
internal validation in the same population or external val-
idation in an independent sample. Internal validation is
useful to prevent optimistic assessments, but it does not
inform about the performance of the model in other sam-
ples of the same population [60]. Moreover, many methods
of standard internal validation, such as cross-validation,
can still give inﬂated estimates of classiﬁcation accuracy,
even if properly performed. Authors should report whether
they performed (internal or external) validation, and
describe the procedure of the validation process. For
example, for internal validation, authors should describe
what part of the population was used to derive the risk
model and what part was used for the validation, and
whether they, for example, used cross validation and
bootstrapping techniques [60]. For external validation, they
should describe the populations that are used for the vali-
dation, particularly the comparability with the population
that was used to derive the risk model. If the model is
already validated elsewhere in previous research, this
should also be stated. So far, none of the genetic risk
prediction studies had performed an external validation of
the risk model [3].
Item 11: Specify how missing data were handled
Examples ‘‘Variables with missing values were hyperten-
sion (1%), smoking (10%), BMI (14%), plasma HDL
cholesterol (19%), plasma LDL cholesterol (20%), and
plasma triglycerides (16%). We applied a multiple impu-
tation method (aregImpute function of the R statistical
package; version 2.5.1; www.r-project.org) to impute these
missing values in our Cox proportional hazards models
because imputation decreases bias in the hazard ratios that
may occur when patients with incomplete information are
excluded from the analysis. In a secondary analysis, we
used the full data set (n = 2,145) and multiple imputation
to impute both missing values for conventional risk factors
and missing genotype data. This analysis gave discrimi-
native accuracies for the 3 prediction models virtually
identical to the analysis without imputation of missing
genotype data […].’’ [36]
Explanation Missing data are inevitable in observational
studies. Authors should specify the percentage of missing
values in their data, indicate whether there are theoretical
or empirical grounds that missingness could be non-ran-
dom, and specify how missing data were handled in the
analyses. Authors should specify the methods used to deal
with the missing data (e.g., complete case analysis, impu-
tation, reweighting) and the assumptions that underlie this
choice. Assumptions may include the distribution of the
data and whether data were missing completely at random,
or related to other variables, including the outcome of the
study [61].
Item 12: Specify all measures used for the evaluation
of the risk model including, but not limited to, measures
of model ﬁt and predictive ability
Examples ‘‘We calculated odds ratios and 95% conﬁdence
intervals associated with each additional risk allele for each
SNP individually and in the genotype score. Using C sta-
tistics …, we evaluated the discriminatory capability of the
models with the genotype score as compared with the
models without the genotype score. We also evaluated risk
reclassiﬁcation with the use of the genotype score,
according to the method developed by Pencina et al. for
determining net reclassiﬁcation improvement. We assessed
model calibration using the Hosmer–Lemeshow chi-square
test. We used categories of genotype score to calculate
likelihood ratios and posterior probabilities of diabetes.
Statistical analyses were performed with the use of SAS
software, version 8 (SAS Institute). A two-tailed P value of
less than 0.05 was considered to indicate statistical sig-
niﬁcance.’’ [48]
‘‘Our primary measure of discrimination was the Harrell
c-index, a generalization of the area under the receiver-
operating characteristic curve that allows for censored data.
The c-index assesses the ability of the risk score to rank
women who develop incident cardiovascular disease higher
than women who do not. We assessed general calibration
across deciles of predicted risk by using the Hosmer–
Lemeshow goodness-of-ﬁt test to compare the average
predicted risk with the Kaplan–Meier risk estimate within
each decile and considered a chi-square value of 20 or
higher (P\0.01) to be poor calibration. We assessed risk
reclassiﬁcation by sorting the predicted 10-year risk for
each model into 4 categories (\5, 5 to\10%, 10 to\20%,
and C20%). We then compared the assigned categories for
a pair of models. For each pair, we calculated the propor-
tion of participants who were reclassiﬁed by the compari-
son model versus the reference model; we considered
reclassiﬁcation to be correct if the Kaplan–Meier risk
estimate for the reclassiﬁed group was closer to the com-
parison category than the reference. We computed the
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which assesses agreement between the Kaplan–Meier risk
estimate and predicted risk within the reclassiﬁed catego-
ries. We also computed the Net Reclassiﬁcation Improve-
ment, which compares the shifts in reclassiﬁed categories
by observed outcome, and the Integrated Discrimination
Improvement, which directly compares the average dif-
ference in predicted risk for women who go on to develop
cardiovascular disease with women who do not for the 2
models, on the women who were not censored before
8 years.’’ [56]
Explanation A thorough assessment of a risk prediction
model comprises many different aspects, but generally
includes at least the following questions: (1) How well does
the model ﬁt the underlying data?; and (2) What is the
predictive ability of the model? Several measures are
available to answer each question, and the methods section
should clearly describe which measures were used to
answer which questions [4, 62]. Measures of model ﬁt (also
referred to as calibration) include the Hosmer–Lemeshow
statistic, R
2, log-likelihood and Akaike information crite-
rion (AIC), and measures of predictive ability (also called
discrimination measures) include the area under the recei-
ver operating characteristic curve (AUC), discrimination
slope and Brier score. These measures can be accompanied
by ﬁgures and tables, including calibration plots (see in
[60]), risk distributions (see Fig. 1), AUC plots (see Fig. 2),
discrimination plots (see in [63]) and predictiveness curves
(see in [64]). The description of the methods used should
clarify also what measures of uncertainty are employed
(e.g., 95% conﬁdence intervals) and specify any tests used
to determine the signiﬁcance of the ﬁndings. When P-val-
ues are reported, authors should indicate what P-value
threshold they considered for statistical signiﬁcance.
When two risk models are compared and one is an
expanded version of the other, the assessment of the risk
models includes the two questions for each model.
Increases in AUC or in discrimination slope (called inte-
grated discrimination improvement, IDI) provide simple
ways to assess improvement of one model over the other
[58]. Recent studies have also assessed whether the
improvement of risk models also reclassiﬁes people into
different risk categories [2, 65]. These measures of
reclassiﬁcation, such as the percentage of total reclassiﬁ-
cation and net reclassiﬁcation improvement [4, 66], are
calculated from a reclassiﬁcation table (Table 7). When risk
categories are used (e.g., for the calculation of reclassiﬁ-
cation measures), the rationale for the cut-off values should
be presented with either appropriate reference to previous
work showing that this is a standard choice, or appropriate
justiﬁcation for the choice of cut-offs made by the authors.
When several different cut-off categorizations have been
studied, all of them should be reported.
Fig. 1 Example: Distribution of the number of disease risk alleles
among sporadic long-lived participants of the Leiden 85 Plus Study
and Netherlands Twin Register controls [94]
Fig. 2 Example: ROC curve analysis of adding genetic variables to
clinical risk factors for the prediction of age-related macular
degeneration. Area under the receiver operating characteristic curve
for the age-related macular degeneration (AMD). The risk models
were constructed from published genotype/exposure frequencies and
odds ratios [6], using a simulation method that has been described
previously [95]. The clinical prediction model was based on age, sex,
education, baseline AMD grade, smoking, body mass index and
treatment. The added genetic factors were six single nucleotide
polymorphisms. The curves indicate the sensitivity and 1-speciﬁcity
for every possible cut-off value of predicted risks. The diagonal line
indicates a hypothetical random predictor, which AUC equals 0.50
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123Item 13: Describe all subgroups, interactions
and exploratory analyses that were examined
Examples (Subgroups) ‘‘[In introduction:] However, it
remains unknown whether all these genetic and environ-
mental factors act independently or jointly and to what
extent they as a group can predict the occurrence of AMD
or progression to advanced AMD from early and inter-
mediate stages. Such information may be useful for
screening those at high risk due to a positive family history
or having signs of early or intermediate disease, among
whom some progress to advanced stages of AMD with
visual loss. … [In Methods:] Individuals with advanced
AMD were compared to the control group of persons with
no AMD, and progressors were compared to nonprogres-
sors with regard to genotype and risk factor data.’’ [6]
(Interactions) ‘‘Multiplicative interactions were tested
for each pair of [all 6] SNPs by including both main effects
and an interaction term (a product of two main effects) in a
logistic regression model.’’ [67]
Explanation For the evaluation of the predictive per-
formance there might be subgroups in which the risk model
performs better than in the initial study population, and
there might be genetic variants that jointly have a larger
impact on disease risk. The large number of possible
analyses that include subgroups or interactions, however,
increases the likelihood of ﬁnding at least some statistically
signiﬁcant effect by chance [68]. Authors should therefore
not only clarify all additional subgroup analyses they per-
formed, but also indicate whether these were planned based
on a priori clinical or epidemiological evidence, or arose in
an exploratory fashion. Similarly, authors should also
explain whether interaction effects were considered and, if
so, which ones and why, and how the selection in the ﬁnal
model was done (see item 9). These descriptions should
include any methods used to prevent over interpretation of
the results, e.g., methods that adjust the P-value thresholds
to adjust for multiple testing. Planned analyses of sub-
groups and interactions should logically follow from the
introduction (see item 3); exploratory analyses can be
introduced in the methods.
Results
Item 14: Report the numbers of individuals at each stage
of the study. Give reasons for non-participation at each
stage. Report the number of participants not genotyped,
and reasons why they were not genotyped
Examples ‘‘Among 3648 identiﬁed subjects with prostate
cancer, 3161 (87%) agreed to participate. DNA samples
from blood, tumor–node–metastasis (TNM) stage, Gleason
grade (as determined by biopsy), and levels of prostate-
speciﬁc antigen (PSA) at diagnosis were available for 2893
subjects (92%).’’ [67]
‘‘[In methods:] In short, the Rotterdam Study is a pro-
spective, population based, cohort study among 7,983
inhabitants of a Rotterdam suburb, designed to investigate
determinants of chronic diseases … [In Results:] A total of
6,544 participants were successfully genotyped for at least
one polymorphism. Complete genotype information on all
polymorphisms was present in 5,297 subjects (of whom
490 were incident cases and 545 were prevalent cases).’’
[42]
Explanation The study report should clearly present the
number of participants that were eligible for the study and
how many were included in the ﬁnal analyses. The authors
should report the main reasons for non-participation, so
that the reader can judge the extent to which the population
available for the analyses is a representative selection of
those who were eligible. Any evidence for missingness not
completely at random should be presented [69]. A ﬂow-
chart can help clarify complex datasets, and is particularly
useful for follow-up studies. A ﬂowchart presents the exact
numbers and the structure of the study (see example in
[29]). When a ﬂowchart of the study has been previously
published and the ﬂow of participants is the same, a ref-
erence to the earlier publication can save space. For cohort
studies, descriptive information about the follow-up time,
e.g., in terms of the range, median and interquartile range
of follow-up duration, should be provided.
Frequently, studies do not have complete genotype
information for all participants for many reasons, including
budget issues, unavailability of DNA material and geno-
typing quality issues. Because some reasons might impact
the validity of the study, the number of participants that
were not genotyped and the reasons should be reported. An
example is survivor bias, which might occur when geno-
typing is performed on DNA obtained in one of the follow-
up assessments of a cohort study (see example [52]).
Item 15: Report demographic and clinical characteristics
of the study population, including risk factors used
in the risk modeling
Examples ‘‘The mean age of cases was similar to that of
controls, 59.9 and 59.6 years, respectively. In comparison
with controls, a higher proportion of cases had a ﬁrst-
degree family history of prostate cancer (see Table 4). The
majority of cases had serum PSA values of 4.0–9.9 ng/ml
at diagnosis, localized stage disease and Gleason scores of
5 or 6; most were treated with radical prostatectomy.’’ [31]
Explanation The authors should describe their popula-
tions in as much detail as is needed for the readers to judge
the generalizability of the results. This description should
include relevant demographic information, such as age, sex
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123and ethnicity, and information on other risk factors and
relevant pathology, e.g., early disease characteristics and
comorbidity. Continuous variables are preferably described
by means and standard deviations, and when their distri-
butions are skewed, by medians and inter-quartile ranges.
Variables that have a small number of response categories
are preferably presented as percentages and numbers. This
descriptive information is preferably presented separately
for those people with and without the outcome of interest.
Item 16: Report unadjusted associations
between the variables in the risk model(s) and the outcome.
Report adjusted estimates and their precision from the full
risk model(s) for each variable
Examples ‘‘Table 5 displays the unadjusted association
between demographic, environmental, and genetic vari-
ables and incident advanced AMD as well as the sample
sizes within the groups. All factors except gender were
related to progression. Baseline macular status was
strongly related to progression. Both modiﬁable factors
(smoking and BMI) and genetic variants were also asso-
ciated with worsening of macular disease over time. The
antioxidant/mineral treatment group had a lower rate of
progression. … Table 6 displays the multivariate adjusted
ORs for incident advanced AMD and shows that, after
adjustment for genotypes, older age, smoking, and higher
BMI were related to a higher rate of progression. Baseline
grade was a strong predictor of incident advanced AMD,
and antioxidant–mineral treatment was protective. The two
CFH variants each independently increased risk of pro-
gression about two- to threefold, with similar increased risk
for C3, comparing the homozygous risk and nonrisk
genotypes. Variants in the two complement genes C2 and
CFB reduced risk, although the association with CFB was
not signiﬁcant for progression to incident advanced
AMD. …’’ [6]
Explanation To understand which risk factors have
contributed to the distribution in risk predictions, authors
should report model estimates for each, e.g., regression
Table 4 Example Table:
Demographic and clinical
characteristics of study
participants with and without
prostate cancer
Adapted from [31]
Characteristic Cases Controls
N = 1,308 % N = 1,266 %
Age (years)
35–49 102 7.8 107 8.5
50–54 188 14.4 178 14.1
55–59 325 24.9 343 27.1
60–64 395 30.2 334 26.4
65–69 153 11.7 160 12.6
70–74 145 11.1 144 11.4
1st degree family history of prostate cancer
No 1,025 78.4 1,125 88.9
Yes 283 21.6 141 11.1
PSA at diagnosis or interview (ng/ml)
0–3.9 178 13.6 351 27.7
4.0–9.9 721 55.1 33 2.6
10.0–19.9 190 14.5 6 0.5
C 20.0 118 9.0 0 –
Gleason score
2–4 66 5.1
5–6 681 52.2
7 = 3?4 355 27.2
7 = 4?3 76 5.8
8–10 126 9.7
Primary treatment
Radical prostatectomy 770 58.9
Radiation 352 26.9
Androgen deprivation therapy 60 4.6
Other treatment 11 0.8
Active surveillance 115 8.8
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123Table 5 Example Table: Descriptive associations between demographic, environmental and genetic variables and progression to advanced age-
related macular degeneration
Progressors n (%) Nonprogressors n (%) OR (95%CI) P
Total patients 279 1167
Age (year)
\70 137 (49) 743 (64) 1.0
70? 142 (51) 424 (36) 1.8 (1.4–2.4) \0.001
Sex
Female 163 (58) 694 (59) 1.0 0.74
Male 116 (42) 473 (41) 1.0 (0.8–1.4)
Education
BHigh school 119 (43) 383 (33) 1.0 0.002
[High school 160 (57) 784 (67) 0.7 (0.5–0.9)
Baseline AMD grades
2 8 (3) 446 (38) 1.0
3 161 (58) 566 (48) 15.9 (7.7–32.6) \0.001
4 110 (39) 155 (13) 39.6 (18.9–83.0)
Smoking
Never 110 (39) 557 (48) 1.0
Past 137 (49) 564 (48) 1.2 (0.9–1.6) 0.14
Current 32 (11) 46 (4) 3.5 (2.1–5.8) \0.001
BMI
\25 69 (25) 416 (36) 1.0
25–29 130 (47) 484 (41) 1.6 (1.2–2.2) 0.003
30? 80 (29) 267 (23) 1.8 (1.3–2.6) 0.001
Treatment group
Placebo 74 (27) 264 (23) 1.0
Antioxidants 77 (28) 295 (25) 0.9 (0.7–1.3) 0.70
Zinc 67 (24) 294 (25) 0.8 (0.6–1.2) 0.27
Antioxidants and zinc 61 (22) 314 (27) 0.7 (0.5–1.0) 0.056
rs1061170
TT 39 (14) 366 (31) 1.0
CT 116 (42) 521 (45) 2.1 (1.4–3.1)
CC 124 (44) 280 (24) 4.1 (2.8–6.1) \0.001
rs10490924
GG 67 (24) 612 (52) 1.0
GT 138 (49) 446 (38) 2.8 (2.1–3.9) \0.001
TT 74 (27) 109 (9) 6.2 (4.2–9.1)
rs1410996
TT 8 (3) 158 (14) 1.0
CT 74 (27) 472 (40) 3.1 (1.5–6.6) \0.001
CC 197 (71) 537 (46) 7.2 (3.5–15.0)
rs9332739
GG 271 (97) 1,075 (92) 1.0
CG/CC 8 (3) 92 (8) 0.3 (0.2–0.7) 0.005
rs641153
CC 256 (92) 1,023 (88) 1.0
CT/TT 23 (8) 143 (12) 0.6 (0.4–1.0) 0.06
rs2230199
CC 124 (44) 652 (56) 1.0
CG 130 (47) 456 (39) 1.5 (1.1–2.0)
GG 25 (9) 59 (5) 2.2 (1.3–3.7) \0.001
Adapted from [6]
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123coefﬁcients, such as odds ratios or hazard ratios, and
conﬁdence intervals from each full model considered for
all risk factors included. Adjusted estimates should be
presented next to the unadjusted estimates, so that readers
are able to judge the extent to which the ﬁndings change by
the inclusion of other risk factors in the model. This is
particularly relevant for models that combine genetic and
non-genetic risk factors, because non-genetic risk factors
can be intermediate factors in the biological pathway [41]
and many non-genetic risk factors have complex correla-
tion patterns [70, 71]. Note that several studies have pre-
sented adjusted effect sizes for genetic variants (e.g., [42,
48, 51]) that were adjusted only for non-genetic risk fac-
tors. This is not the same as effect sizes for genetic variants
from the full model, where coefﬁcients are additionally
adjusted for the other genetic variants as well. When
regression methods were used for the prediction of risks,
the intercept of the full model should be reported to
facilitate future replication and validation of the risk model
(see Table 6). For complex models where exhaustive
speciﬁcation of parameter estimates is not feasible, authors
should provide software implementations of the risk pre-
diction algorithm (see item 24).
Item 17: Report distributions of predicted risks and/or risk
scores
Examples The distribution of predicted risks or risk scores
is best presented in a ﬁgure, see Fig. 1 [45].
Explanation Distributions of predicted risks inform the
reader about the spread of risks in the population, as well as
the frequencies at the higher and lower ends of the
Table 6 Example Table: Multivariate association between demo-
graphic, environmental, and genetic risk factors and progression to
advanced age-related macular degeneration (AMD)
Regression
Coefﬁcient (bi)
OR (95% CI)* P
Intercept (a) -5.780
Age (year)
B70 0 1.0
[70 0.4116 1.5 (1.1–2.0) 0.008
Sex
Female 0 1.0
Male 0.0688 1.1 (0.8–1.5) 0.68
Education
BHigh school 0 1.0
[High school -0.1280 0.9 (0.6–1.2) 0.42
Baseline grade
2 0 1.0
3 2.3944 11.0 (5.3–22.8) \0.001
4 2.9521 19.1 (8.9–41.2) \0.001
Smoking
Never 0 1.0
Past 0.1211 1.1 (0.8–1.6) 0.47
Current 1.1261 3.1 (1.7–5.6) \0.001
BMI
\25 0 1.0
25–29 0.5170 1.7 (1.2–2.4) 0.006
30? 0.4754 1.6 (1.1–2.4) 0.024
Treatment group
Placebo 0 1.0
Antioxidants -0.1299 0.9 (0.6–1.3) 0.54
Zinc -0.3897 0.7 (0.4–1.0) 0.075
Antioxidants and zinc -0.4973 0.6 (0.4–0.9) 0.023
rs1061170
TT 0 1.0
CT 0.2644 1.3 (0.8–2.1) 0.29
CC 0.6778 2.0 (1.1–3.5) 0.019
P trend 0.014
rs10490924
GG 0 1.00
GT 0.8396 2.3 (1.6–3.3) \0.001
TT 1.3837 4.0 (2.6–6.1) \0.001
P trend \0.001
rs1410996
TT 0 1.0
CT 0.5251 1.7 (0.7–4.0) 0.23
CC 0.8606 2.4 (1.0–5.8) 0.061
P trend 0.029
rs9332739
GG 0 1.0
CG/CC -1.0510 0.4 (0.2–0.8) 0.010
Table 6 continued
Regression
Coefﬁcient (bi)
OR (95% CI)* P
rs641153
CC 0 1.0
CT or TT -0.2147 0.8 (0.5–1.4) 0.42
rs2230199
CC 0 1.0
CG 0.3679 1.4 (1.1–2.0) 0.022
GG 0.5970 1.8 (1.0–3.2) 0.044
P trend 0.006
Adapted from [6]
* ORs adjusted for age (\70, C70), sex, education (Bhigh school,
[high school), smoking (never, past, current), baseline AMD grade,
BMI (\25, 25–29, 30?), and treatment groups (placebo, antioxidants,
zinc, and antioxidants plus zinc), and all six genetic variants and
associated genotypes as listed in the table. Calculation of the AMD
Progression Risk Score = a ? biXi, where i refers to each of the
variables listed
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123distribution. Preferably the report should present separate
distributions for participants with and those without the
outcome of interest, as this illustrates the discriminative
accuracy of the risk model. The more the two distributions
disperse, the higher the AUC. Authors should label the
highest and lowest category by their actual range at least
once. For example, Fig. 1 shows that the lowest category is
labeled 10–11 risk alleles, rather than 0–11, which informs
readers that none of the participants had 0–9 risk alleles.
Item 18: Report measures of model ﬁt and predictive
ability, and any other performance measures, if pertinent
Examples ‘‘We also evaluated whether genetic risk factors
would further increase the risk imposed by an increase in
the BMI or a decrease in the disposition index. There was a
stepwise increase in diabetes risk with an increasing
number of risk alleles and increasing quartiles of BMI (Fig.
[not shown]) or a disposition index above or below the
median. Therefore, carriers of more than 12 risk alleles
who were in the highest quartile of BMI (263 of 826
subjects vs. 45 of 874 subjects) or who had a low dispo-
sition index (58 of 153 subjects vs. 17 of 168 subjects) had
an odds ratio for type 2 diabetes of 8.0 (95% CI, 5.71 to
11.19; P = 9.1 9 10 - 34) and 5.8 (95% CI, 3.18 to
10.61, P = 1.1 9 10 - 8), respectively (Fig. [not shown]).
The C statistics had minimal yet signiﬁcant improvement
after the addition of data from the genotyped DNA variants
to the clinical model (from 0.74 to 0.75, P = 1.0 9 10 -
4) (Supplementary Table [not shown]). … we also reclas-
siﬁed subjects into three risk categories (0 to B10%,[10 to
B20%, and[20%) using the net-reclassiﬁcation-improve-
ment method (Supplementary Table [not shown]). By
adding genetic factors to clinical factors, we could reclas-
sify 9% of the MPP subjects (P = 2.5 9 10 - 5) and 20%
of the Botnia subjects (P = 0.05) to a higher risk category.
Also, the use of the integrated-discrimination- improve-
ment method, which did not require predeﬁned risk cate-
gories, signiﬁcantly improved the prediction of future
diabetes in both the MPP subjects (P = 3.7 9 10 - 14)
and the Botnia subjects (P = 0.001).’’ [33]
Explanation All measures of model performance that are
reported in the Results section should be described in the
Methods section (see item 12), so that it is clear which
measure is assessed to answer which research question. As
described in item 12, assessment of the performance of the
genetic risk prediction model should include at least
measures of model ﬁt and predictive ability. For measures
of interest, conﬁdence intervals or other pertinent measures
of uncertainty for the estimated values should be reported,
wherever appropriate.
Item 19: Report any validation of the risk model(s)
Examples (Internal validation) ‘‘The epidemiologic-genetic
model ﬁtted our data well with AUC of 0.80 (95% CI, 0.77
to 0.82), 0.81 (95% CI, 0.77 to 0.85), and 0.80 (95% CI,
0.76 to 0.83) for the combined, training, and validation data
sets, respectively (Table [not shown]). … The leave one
out validation algorithm yielded an average prediction
error rate of 28.0, 27.8, and 27.9% for patient cases, con-
trols, and all samples, indicating relatively high discrimi-
natory prediction accuracy of the model.’’ [37]
(External validation) ‘‘We used independent GWAS
samples to replicate the polygenic component, to examine
whether this component is shared with bipolar disorder,
and to demonstrate speciﬁcity by considering non-psychi-
atric diseases. We used the entire International Schizo-
phrenia Consortium (ISC) for the discovery sample […].
The ISC-derived score was highly associated with disease
Table 7 Example Table: Net reclassiﬁcation improvement based on addition of gene count score to Framingham offspring risk score
Framingham offspring
risk score
Framingham offspring risk score plus gene count score Reclassiﬁed Net correctly
reclassiﬁed
\5% 5–10% 10–15% [15% Increased risk Decreased risk
People without diabetes during follow-up
\5% 2,295 48 0 0
5–10% 36 482 43 0 121 64 -1.7%
10–15% 0 19 181 30
[15% 0 0 9 181
People with diabetes during follow-up
\5% 52 8 0 0
5–10% 2 37 3 0 14 11 1.5%
10–15% 0 4 24 3
[15% 0 0 5 64
Adapted from [52]
Net reclassiﬁcation improvement -0.2% (95% CI -5.1 to 4.7); P = 0.94
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123in both European schizophrenia samples (Fig [not
shown]).’’ [72]
Explanation Essentially, the measures that need to be
presented for the validation analyses are the same as
reported for the assessment of the performance of the
model in the derivation population (see items 12 and 18).
If, for reasons of space, authors have to choose between
presenting detailed assessment for the derivation or vali-
dation data, they should choose to report the validation
analyses in more detail.
Item 20: Present results of any subgroup, interaction
or exploratory analyses, whenever pertinent
Examples ‘‘Finally we estimated the two-way interaction
between each combination of the 19 variants (171 combi-
nations) (Supplementary Table [not shown]) and the result
demonstrated few, probably spurious, associations
(P\0.05). As none of the associations was signiﬁcant
after Bonferroni correction we believe that an additive
model between each variant is acceptable. Additionally, we
calculated the AUC under an ROC curve in which a model
including all variants (additive) is compared with a model
including a two-way interaction term in addition to the
variants (interaction). The results showed that if interaction
is included an AUC of 0.56 is reached, which indicates
reduced discriminatory value (Supplementary Table [not
shown]).’’ [30]
‘‘The predictive accuracy of these 4-gene genotypes was
not signiﬁcantly different in study participants in the low-
est, middle, or top tertile of conventional risk factor score
[0.65 (0.55–0.75), 0.63 (0.55–0.72), and 0.60 (0.53–0.67),
respectively; P = 0.66]. Adding APOE genotype alone
signiﬁcantly improved the AUC [0.68 (0.64–0.72);
P\0.01 vs conventional risk factors only], but none of the
other genotypes singly or in pairwise combinations did so
(see Table [not shown]).’’[55]
Explanation In the presentation of subgroups it should
be clear which ﬁndings follow from pre-speciﬁed hypoth-
eses and which follow from exploration of the data. This
distinction is particularly important for the discussion, as
exploratory analyses might lead to incidental ﬁndings that
need more cautious interpretation and replication [73].
Discussion
Item 21: Discuss limitations and assumptions of the study,
particularly those concerning study design, selection
of participants, measurements and analyses, and discuss
their impact on the results of the study
Examples ‘‘One of the limitations of our study is that the 18
SNPs we included are probably insufﬁcient to account for
the familial risk of diabetes. They account for a minority of
diabetes heritability, and the SNP array platforms from
which they were chosen capture only approximately 80%
of common variants in Europeans. …
Our study has other limitations. There were few sig-
niﬁcant associations between individual risk alleles and
diabetes in the Framingham Offspring Study cohort, but
this ﬁnding was expected, given that alleles of small effect
were tested in a community-based sample of modest size,
and the aggregate set of 18 SNPs was predictive of new
cases of diabetes. The participants in the Framingham
Offspring Study are essentially all of European ancestry;
allelic variation may require that different SNPs be used to
generate a genotype score in different ancestry groups. Our
genotype score gave all alleles the same weight; this may
not be a true reﬂection of the biologic basis of type 2
diabetes. We considered the marginal value of the geno-
type score after accounting for only phenotypic risk factors,
without consideration of behavioral risk factors for diabe-
tes. We expect that accounting for unhealthful behaviors
associated with the risk of diabetes would only further
diminish the discriminatory capacity of a genotype score.
However, persons with relatively less healthful lifestyle
behaviors might be more susceptible to genetic risk than
those with more healthful behaviors. Whether the genotype
score would have value in predicting the risk of diabetes in
speciﬁc subgroups that have an elevated risk on the basis of
poor health habits remains to be tested.’’ [48]
Explanation The interpretation of the study should take
proper account of the results in light of all analyses that
were performed. Caution in the interpretation is warranted
when there was considerable opportunity for ﬂexibility in
the analyses, e.g., when arbitrary categories of predicted
risks were considered or when many subgroup analyses
were done. Most studies avoid a comprehensive discussion
of limitations [74] and many authors admit that they fear
that discussion of limitations might make their paper less
attractive for publication [75]. However, this is not the case
[76]. A discussion of the limitations of the study should
help the reader in interpreting the validity of the ﬁndings.
The description of the limitations should include not only
the sources of potential bias and confounding that might
have affected the results, but also the direction and mag-
nitude of their effect [29]. An informative discussion
addresses issues in the design and analyses of the study that
might lead to alternative interpretations of the data than the
one presented in the paper. These can refer to issues that
directly inﬂuence the results, but also to issues that lead to
different inferences drawn about things such as the health
care relevance of the ﬁndings. Examples include charac-
teristics of the study population, selection of participants,
procedures and measures used in data collection, length of
follow-up, unaccounted multiplicity of analyses, and
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123missing data. Any possible threats to the validity of the
results should be addressed in the discussion.
Item 22: Give an overall interpretation of results
considering objectives, limitations, multiplicity of analyses,
results from similar studies, and other relevant evidence
Examples ‘‘In this study, we show that, at a population
level, accumulation of several susceptibility genes for
diabetes is accompanied by a substantial increase in the
risk of having the disease. This was particularly apparent,
in terms of prevalence, among obese individuals. We also
show that the weighted genetic score added some infor-
mation that was not captured by clinical variables,
including family history of diabetes. The present data also
show that weighting the genetic score with the reported
effect of risk alleles provided more predictive value than an
unweighted genetic score generated by counting the num-
ber of risk alleles. The clinical usefulness of the score,
however, remains to be demonstrated.
The present population-based cross-sectional study is in
line with two very recently published prospective studies.
In both of these studies, a high unweighted genetic score
was associated with a marked increase in the incidence of
diabetes. However, the predictive value of this score
beyond clinical variables was modest.’’ [57]
Explanation The interpretation of the study should
compare the study with that of others. Other studies can
include genetic prediction studies on the same outcome,
but also studies that have investigated non-genetic or
combined models. This discussion should compare not
only the main results, but also address whether the design
and conduct of the studies were comparable. Speciﬁc
attention should be given to the genetic variants included in
the risk models, because their number increases with the
rapid developments in gene discovery. Ideally the discus-
sion of other studies should be systematic and any relevant
systematic reviews and meta-analyses might be helpful to
employ in this setting [77]. It would be worthwhile dis-
cussing whether previous evidence is considered to be
subject to selective reporting, which might be quite pre-
valent in prognostic research [10].
Item 23: Discuss the generalizability and, if pertinent,
the health care relevance of the study results
Examples ‘‘Although prospective, the Whitehall II study is
workplace based and therefore not necessarily representa-
tive of the general population. However, the excellent
performance in Whitehall II of the non-genetic risk func-
tions for type 2 diabetes, both of which were developed and
validated in general populations, suggests that this is
unlikely to bias our conclusions substantially. Moreover,
our ﬁndings are consistent with those of prospective studies
set in representative general populations. Our ﬁndings are
also not generalizable to people of non-European ancestry,
who we excluded from this analysis. Although DNA was
collected some time after baseline, which could have
introduced a survivor bias, we think that this is unlikely to
have affected our results given the modest effect of the
alleles we studied on risk of diabetes and the long natural
history of the development of the life threatening compli-
cations of diabetes… Phenotype based risk models (the
Framingham offspring and Cambridge risk scores) pro-
vided greater discrimination for type 2 diabetes than did
models based on 20 common independently inherited
alleles associated with risk of type 2 diabetes. The addition
of 20 common genotypes associated with modest risk to
phenotype based risk models produced only minimal
improvement in the accuracy of risk estimation assessed by
recalibration and at best a minor net reclassiﬁcation
improvement. The major translational application of the
currently known common, small effect genetic variants
inﬂuencing susceptibility to type 2 diabetes is likely to
come from the insight they provide on causes of disease
and potential therapeutic targets.’’ [52]
Explanation Generalizability refers to the external
validity or applicability of the risk model in other popu-
lations than the one used for the development of the model.
Discussion of generalizability should include reference to
the representativeness of the study population in compari-
son with the (future) target population for testing. Differ-
ences in key demographic variables, such as in sex, age and
important risk factors, should be mentioned.
While most studies currently do not have direct rele-
vance to health care or disease prevention [41], genetic risk
prediction studies sometimes are interpreted with too much
optimism [60, 78] and expectations run high [79]. One of
the reasons is that clinical or public health relevance is
concluded from statistical signiﬁcance. However, in large-
scale population-based studies, minor increases in predic-
tive performance or low percentages of reclassiﬁcation
could be statistically signiﬁcant without being clinically
relevant. When interpreting the clinical relevance, authors
should consider (1) the efforts it takes to obtain the addi-
tional genotype information, (2) the impact genetic results
might have on medical or public health decision making
and on expected health beneﬁts, and ﬁnally, (3) the extent
to which these beneﬁts will outweigh the potential harms
related to genetic testing and be affordable. A consider-
ation of what information is needed might help prevent
overoptimistic interpretations. Describe what evidence is
still needed before health care implementation can be
considered, for example by referencing the stage of trans-
lational research the study ﬁts in [1]. The latter also
includes a reﬂection on whether the population investigated
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123is an appropriate representation of the target population and
whether the risk period (e.g., 5-year risk) and the outcome
are clinically relevant.
Supplementary information
Item 24: State whether databases for the analyzed data,
risk models and/or protocols are or will become publicly
available and if so, how they can be accessed
Explanation With the advances in genomics research, data
and analytic plans of genetic risk prediction studies become
increasingly complex. So far, most empirical studies have
used logistic or Cox proportional hazards regression anal-
yses [3], but other methods including support vector
machine learning, fuzzy logic, neural networks and clas-
siﬁcation trees have been applied [80, 81]. There is
increasing appreciation that it is important for these com-
plex and extensive data to be publicly available. This
allows scrutiny of the process and the results by other
investigators, and appropriate use of these data for further
analyses, e.g., validation studies and meta-analyses. For
some ‘omics’ ﬁelds, public availability of data and proto-
cols is a prerequisite for publication in speciﬁc journals,
e.g., all gene expression proﬁling studies need to do this as
a prerequisite for publication in Nature Genetics (http://
www.nature.com/authors/editorial_policies/availability.html),
although full deposition of data and protocols has not yet
been achieved [82]. For studies of gene-phenotype asso-
ciations, initiatives such as the Database of Genotype and
Phenotype (dbGAP) and the Genetic Association Infor-
mation Network (GAIN) are promoting the public data
availability of genotype-phenotype data [83, 84].
Funding
Item 25: Give the source of funding and the role
of the funders for the present study. State whether there are
any conﬂicts of interest
Examples ‘‘This study was supported by grants from the
National Heart, Lung, and Blood Institute and National
Cancer Institute, National Institutes of Health; the Donald
W. Reynolds Foundation; and the Leducq Foundation.
Additional support for DNA extraction, reagents, and data
analysis was provided by Roche Diagnostics and Amgen.
Genotyping of the 9p21.3 variant was performed by Celera.
The funding sources had no role in the design, conduct, or
reporting of this study or the decision to submit the man-
uscript for publication.’’ [56]
Explanation Authors should disclose any funding they
received to carry out the study, and state what the role of
the funding agency/agencies was in the design, conduct and
analyses of the study. Given the potential commercial
interests in predictive tests that could be used in large
populations of diseased and healthy people, both inside and
outside health care practice, any ﬁnancial or other conﬂicts
of interest should be transparent. Conﬂicts of interest can
impact all stages of the research, including the study
design, choice of exposures, outcomes, statistical methods
and selective interpretation and publication of results
[29, 85].
Concluding remarks and future directions
High quality reporting reveals the strengths and weak-
nesses of empirical studies, facilitates the interpretation of
the scientiﬁc and health care relevance of the results, in
particular within the framework of systematic reviews and
meta-analyses, and helps build a solid evidence base for
moving genomic discoveries into applications in health
care practice. The GRIPS guidelines were developed to
improve the transparency, quality and completeness of the
reporting of genetic risk prediction studies. GRIPS does not
prescribe how studies should be designed, conducted and
analyzed, and therefore, the guidelines should not be used
to assess the quality of empirical studies [86]. The guide-
lines should only be used to check whether all essential
items are adequately reported.
The GRIPS guidelines were developed by a multidisci-
plinary group of 25 experts, seven of whom were also part
of the STREGA initiative [17]. Taking advantage of their
earlier work, we organized the GRIPS workshop and
manuscript writing along the same lines. The strategy we
followed in developing our guidelines is consistent with the
recommendations proposed in a recent paper on how to
develop health research reporting guidelines [87], which
was published after our workshop. In short, we had
reviewed genetic risk prediction studies and identiﬁed the
need for guidance [3, 41], prepared a proposal for GRIPS
on the basis of previous guidelines for other studies [17–
19], organized a workshop to discuss each item of the
proposal in-depth, had several consultation rounds for the
writing of this paper and pilot-tested the checklist.
Guidelines have been developed for a wide range of
empirical and review studies [15], but it should be
acknowledged that their uptake and impact on reporting
has not been extensively investigated. Several studies have
shown that reporting guidelines do improve the reporting
of studies, but there is still room for improvement [88, 89].
For example, a comparison of randomized controlled trials
published in 2000 and in 2006 showed that more recom-
mended items were addressed in the papers, but that
reporting remained suboptimal [89]. Fortunately, correct
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123reporting of items was more frequent among papers pub-
lished in journals that endorsed the CONSORT guidelines
compared with journals that did not. We agree with the
researchers from the EQUATOR project that ‘‘[reporting
guidelines] improve the accuracy and transparency of
publications, thus facilitating easier and more reliable
appraisal of quality and relevance’’ [90].
The methodology for designing and assessing genetic
risk prediction models is still developing. For example,
newer measures of reclassiﬁcation were ﬁrst introduced in
2007 [91] and several alternative reclassiﬁcation measures
have been proposed [4]. Which measures to apply and
when to use measures of reclassiﬁcation is still subject to
ongoing evaluation and discussion [65]. Furthermore,
alternative strategies for constructing risk models other
than simple regression analyses are being explored, and
these might add increasing complexity to the reporting. In
formulating the items of the GRIPS Statement, these
methodological advances were anticipated. It was for this
reason that the GRIPS Statement recommends how a study
should be reported and not how a study should be con-
ducted or analyzed. Therefore, methodological and ana-
lytical developments will not immediately impact the
validity and relevance of the items, but the GRIPS State-
ment will be updated when this is warranted by essential
new developments in the construction and evaluation of
genetic risk models.
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